The Policy-Driven PMA Pivot Series

The life sciences industry is entering a period where policy is no longer a downstream consideration—it is actively shaping the commercial trajectory of products from the earliest stages of development. The Policy-Driven PMA Pivot Series explores how evolving healthcare policy, reimbursement dynamics, and pricing pressures are fundamentally changing how pharmaceutical and biotech companies approach market […]